IPG Photonics IPGP reported first-quarter 2026 adjusted earnings of 29 cents per share, which missed the Zacks Consensus Estimate by 9.4% and decreased 6% year over year.
Revenues of $265.5 million increased 16.5% year over year and beat the consensus mark by 3.9%. Emerging growth products accounted for 53% of total revenue in the quarter.
IPGP Revenue Mix Tilts Toward Industrial Solutions
IPGP’s first-quarter growth was driven by improved demand in Industrial Solutions. Industrial Solutions revenues were $227.6 million, representing 86% of total sales and rising 21% year over year, supported by higher revenues in welding, cutting, marking and cleaning applications.
Advanced Solutions revenues were $37.9 million, down 5% year over year. Management noted that growth in medical and semiconductor applications was offset by lower micromachining sales tied to cyclical demand in solar cell manufacturing, alongside lower defense revenue.
IPG Photonics Corporation Price, Consensus and EPS Surprise
IPG Photonics Corporation price-consensus-eps-surprise-chart | IPG Photonics Corporation Quote
IPG Photonics Benefits From Battery And Medical Demand
Within Industrial Solutions, IPG Photonics highlighted continued strength in battery manufacturing demand, which supported results in welding and cutting. The company also pointed to progress in expanding system-level offerings, an area it said is helping IPGP move up the value chain by integrating fiber lasers into complete solutions across applications like welding and cleaning.
In Advanced Solutions, IPG Photonics emphasized traction in medical and semiconductor markets. Medical revenues grew significantly year over year, aided by sales to a new customer, and the company expects several new product approvals and introductions across 2026 and 2027. Semiconductor revenue also improved as IPG ramps new business in lithography, metrology and inspection with large equipment manufacturers.
IPGP Margins Hit by Tariffs Despite Inventory Improvements
Profitability reflected a mix of operational progress and external cost pressure. GAAP gross margin was 37.5% versus 39.4% in the year-ago quarter, while adjusted gross margin was 37.8% compared with 40% a year ago. Management attributed the year-over-year decline primarily to tariffs and higher product costs, partially offset by lower inventory provisions tied to improved inventory management.
Sequentially, both GAAP and adjusted gross margins improved, benefiting from improved absorption and lower inventory provisions. The company reiterated its focus on pricing and cost-reduction initiatives to support margin improvement, while noting that underabsorbed expenses remain higher than targeted in the medium term.
Operating expenses were impacted by a significant one-time item. Total GAAP operating expenses were $107.2 million, which included a $13.5 million settlement payment and license related to an agreement with TRUMPF Laser- und Systemtechnik, settling all parts of litigation worldwide. Excluding the settlement payment, litigation expenses, amortization and acquisition-related expenses, adjusted operating expenses were approximately $91 million.
GAAP operating loss was $7.7 million in the reported quarter, compared with operating income of $1.8 million in the year-ago quarter. On an adjusted basis, operating income was $9.3 million, up 21% year over year, highlighting that the primary variance in GAAP profitability was tied to non-recurring items.
IPGP Maintains Strong Liquidity and a Debt-Free Balance Sheet
IPGP ended the first quarter with $813 million in cash and short-term investments, plus $71 million in long-term investments, and no debt. Inventories stood at $319 million, while days sales outstanding were 65.
Cash used in operations was $5.5 million in the first quarter, a period management described as typically weaker for cash generation due to annual bonus payments. Capital expenditures were $16.3 million, reflecting the timing of investments in the company’s major fiber manufacturing facility in Germany.
IPG Photonics Issues Q2 View and Flags Tariff Impact
For the second quarter of 2026, IPG Photonics expects revenues of $260 million to $290 million. Adjusted gross margin is projected between 37% and 40%, including an estimated tariff-related impact of about 150 basis points.
The company guided adjusted operating expenses of $92 million to $95 million and expects adjusted earnings between 25 cents and 55 cents per share. Adjusted EBITDA is expected to be between $32 million and $48 million, with management noting a cautiously optimistic stance that assumes a generally stable operating environment.
Zacks Rank & Stocks to Consider
IPG Photonics currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Computer and Technology sector that are set to report their quarterly results are Docebo DCBO, Diodes DIOD and Keysight Technologies KEYS. Each of the three stocks carries a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Diodes, Docebo and Keysight Technologies are set to report their quarterly results on May 7, 8 and 19, respectively. Year to date, shares of Diodes and Keysight Technologies have jumped 128% and 75.2%, respectively, while Docebo has dropped 8.4%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Diodes Incorporated (DIOD): Free Stock Analysis Report
Keysight Technologies Inc. (KEYS): Free Stock Analysis Report
IPG Photonics Corporation (IPGP): Free Stock Analysis Report
Docebo Inc. (DCBO): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).